<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753855</url>
  </required_header>
  <id_info>
    <org_study_id>TELAPK-2015</org_study_id>
    <nct_id>NCT02753855</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Telavancin in Normal and Obese Subjects</brief_title>
  <official_title>Pharmacokinetics of Telavancin in Normal and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Theravance Biopharma Antibiotics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize plasma and urinary concentrations of telavancin
      following intravenous administration of a single dose of telavancin in healthy subjects who
      are normal weight, overweight, and obese.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase I, open-label, single-dose pharmacokinetic study in healthy adult male
      and female subjects. Eligible subjects will be assigned to one of four groups based on their
      body mass index and total body weight. Subjects will receive a single dose of telavancin
      depending on subject's group as a 1-hour intravenous infusion. Serial blood and urine samples
      will be collected over 12 hours to determine serum and urinary pharmacokinetics of
      telavancin. Subjects will return for blood and urine sample collection at 24 and 48 hours.
      Safety evaluations will be assessed throughout the study and will include physical
      examination, vital sign monitoring, clinical laboratory tests, monitoring of adverse events,
      and markers of kidney injury.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number (%) of adverse events of any severity regardless of relationship to study drug</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area-under-the-plasma concentration-time curve (AUC0-infinity)</measure>
    <time_frame>48 hours</time_frame>
    <description>To estimate the telavancin pharmacokinetic parameter area-under-the-plasma concentration-time curve (AUC0-infinity) after a single dose of telavancin in healthy adult participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>To estimate the telavancin pharmacokinetic parameter maximum plasma concentration (Cmax) after a single dose for intravenously dosed telavancin to healthy adult participants</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telavancin Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of telavancin administered as a 1-hour intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telavancin</intervention_name>
    <description>A single dose of telavancin as a 1-hour intravenous infusion</description>
    <arm_group_label>Telavancin Administration</arm_group_label>
    <other_name>Vibativ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult subjects, 18 to 50 years

          -  Nonsmokers within the last 1 year

          -  Weight &gt; 110 lbs

        Exclusion Criteria:

          -  History of significant hypersensitivity reaction or intolerance to telavancin

          -  Aspartate or alanine aminotransferase &gt; 1.5 times the upper limit of normal

          -  Estimated creatinine clearance &lt;60 mL/minute and serum creatinine &gt;1.5 mg/dL

          -  Female subjects who are pregnant or breast feeding

          -  History of alcohol or substance abuse or dependence within the last 1 year

          -  Use of prescription or nonprescription drugs (unless hormonal contraceptives) within 7
             to 14 days prior to telavancin administration

          -  Participation in a clinical trials within last 30 days

          -  Donated blood (&gt;500 mL) within the last 56 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith A. Rodvold, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Keith A. Rodvold</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telavancin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

